Studies on the teratogen pharmacophore of valproic acid analogues: Evidence of interactions at a hydrophobic centre

European Journal of Pharmacology

Volumn 354, Issue 2-3, 1998, Pages 289-299

  Bojic, Ursula ^b   Ehlers, Katharine ^b   Ellerbeck, Ursula ^b   Bacon, Christopher L ^a   O'Driscoll, Esther ^a   O'Connell, Cormac ^a   Berezin, Vladimir ^c   Kawa, Anna ^c   Lepekhin, Eugene ^c   Bock, Elisabeth ^c   Regan, Ciaran M ^a   Nau, Heinz ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Differentiation; Embryo, mouse; NCAM (neural cell adhesion molecule); Neural tube defect; Proliferative rate

Indexed keywords

NERVE CELL ADHESION MOLECULE; VALPROIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SYNTHESIS; EMBRYO; EMBRYOTOXICITY; EXENCEPHALY; GLIOMA; HYDROPHOBICITY; MOUSE; NEURAL TUBE DEFECT; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TERATOGENICITY;

ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOMA; MALE; MICE; NEURAL CELL ADHESION MOLECULES; NEUROBLASTOMA; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TERATOGENS; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 0031694133     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00462-2     Document Type: Article

References (54)

1. Bacon, C.L., O'Driscoll, E., Regan, C.M., 1997. Valproic acid suppresses G1 phase-dependent sialylation of a 65-kDa glycoprotein in the C6 glioma cell cycle. Int. J. Dev. Neurosci. 15, 777-784.
2. Bacon, C.L., Berezin, V., Bode, G., Bock, E., Bojic, U., Doherty, P., Ehlers, K., Ellerbeck, U., Julien, P., Kawa, A., Maar, T.E., Nau, H., Pirovano, R., Regan, C.M., Schousboe, A., Spezia, F., Walsh, F.S., Williams, E.J., 1998. Cell proliferation, migration and CAM-dependent neurite outgrowth as developmental in vitro endpoints for screening teratogenic potential: application to valproic acid and related analogues of varying potency. Toxicol. Vitro 12, 101-109.
3. Berezin, V., Kawa, A., Bojic, U., Foley, A., Nau, H., Regan, C.M., Edvardsen, K., Bock, E., 1996. Teratogenic potency of valproate analogues evaluated by quantitative estimation of cellular morphology in vitro. Toxicol. Vitro 10, 585-594.
4. 2+ dependent and independent cell adhesion molecules. Proc. Natl. Acad. Sci. USA 84, 2555-2559.
5. Bloch, R., 1992. Clusters of neural cell adhesion molecule at sites of cell-cell contact. J. Cell Biol. 116, 449-463.
6. Bojic, U., Elmazar, M.M.A., Nau, H., 1996. Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Chem. Res. Toxicol. 9, 866-870.
7. Braun, A.G., Buckner, C.A., Emerson, D.J., Nichinson, B.B., 1982. Quantitative correspondence between the in vivo and in vitro activity of teratogenic agents. Proc. Natl. Acad. Sci. USA 79, 2056-2060.
8. Chen, G., Manji, H.K., Wright, C.B., Hawver, D.B., Potter, W.Z., 1994. Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro. J. Neurochem. 63, 2361-2364.
9. Chen, G., Manji, H.K., Hawver, D.B., Wright, C.B., Potter, W.Z., 1996. Effects of valproic acid on beta-adrenergic receptors, G-proteins and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology 15, 271-280.
10. Cinatl, J. Jr., Cinatl, J., Scholz, M., Driever, P.H., Henrich, D., Kabickova, H., Vogel, J.-U., Doerr, H.W., Kornhuber, B., 1996. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anti-Cancer Drugs 7, 766-773.
11. Copp, A.J., Brook, F.A., Roberts, H.J., 1988. A cell-type-specific abnormality of cell proliferation in mutant (curly tail) mouse embryos developing spinal neural tube defects. Development 104, 285-295.
12. Courage-Maguire, C., Bacon, C.L., Regan, C.M., Nau, H., 1997. Correlation of in vitro anti-proliferative potential with in vivo teratogenicity in a series of valproate analogues. Int. J. Dev. Neurosci. 15, 37-43, (Erratum 15, 693-694).
13. Dencker, L., Nau, H., D'Argy, R., 1990. Marked accumulation of valproic acid in embryonic neuroepithelium of the mouse during early organogenesis. Teratology 41, 699-706.
14. Doherty, P., Fruns, M., Seaton, P., Dickson, G., Barton, C.H., Sears, T.A., Walsh, F.S., 1990. A threshold effect of the major isoforms of NCAM on neurite outgrowth. Nature 343, 464-466.
15. Elmazar, M.M.A., Hauck, R.-S., Nau, H., 1993. Anticonvulsant and neurotoxic activities of twelve analogues of valproic acid. J. Pharm. Sci. 82, 1255-1258.
16. Felipo, V., Miñana, M.-D., Grisolla, S., 1990. A specific inhibitor of protein kinase C induces differentiation of neuroblastoma cells. J. Biol. Chem. 265, 9599-9601.
17. Fischer, E., Wittfoht, W., Nau, H., 1992. Quantitative determination of valproic acid and 14 metabolites in serum and urine by gas chromatography/mass spectrometry. Biomed. Chromatogr. 6, 24-29.
18. Franks, N.P., Lieb, W.R., 1991. Stereospecific effects of inhalational general anesthetic optical isomers on nerve ion channels. Science 254, 427-430.
19. Franks, N.P., Lieb, W.R., 1994. Molecular and cellular mechanisms of general anaesthesia. Nature 367, 607-614.
20. Haddox, M.K., Russell, D.H., 1979. Cell cycle-specific locus of vitamin A inhibition of growth. Cancer Res. 39, 2476-2480.
21. Hankin, M.H., Lagenauer, C.F., 1994. Cell adhesion molecules in early developing mouse retina: Retinal neurons show preferential outgrowth in vitro on L1 but not NCAM. J. Neurobiol. 25, 5472-5487.
22. Hauck, R.S., Nau, H., 1989. Zu den strukturellen Grundlagen der teratogenen Wirkung des Antiepileptikums Valproinsäure (valproic acid): 2-n-propyl-4-pentinsäure, das erste Strukturanalogon höherer Teratogenität als valproic acid. Naturwissenschaften 76, 528-529.
23. Hauck, R.-S., Nau, H., 1992. The enantiomers of the valproic acid analogue 2-n-propyl-4-pentynoic acid (4-yn-valproic acid): asymmetric synthesis and highly stereoselective teratogenicity in mice. Pharm. Res. 9, 850-855.
24. Hauck, R.-S., Elmazar, M.M.A., Plum, C., Nau, H., 1992. The enantioselective teratogenicity of 2-n-propyl-4-pentynoic acid (4-yn-valproic acid) is due to stereoselective intrinsic activity and not difference in pharmacokinetics. Toxicol. Lett. 60, 145-153.
25. Husmann, M., Görgen, I., Weisgerber, C., Bitter-Suermann, D., 1989. Up-regulation of embryonic NCAM in an EC cell line by retinoic acid. Dev. Biol. 136, 194-200.
26. Kao, J., Brown, N.A., Schmid, B., Goulding, E.H., Fabro, S., 1981. Teratogenicity of valproic acid: in vivo and in vitro investigations. Teratog. Carcinog. Mutag. 1, 367-382.
27. Litchfield, J.T., Wilcoxon, F., 1949. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 257, 20-31.
28. Löscher, W., 1993. Effects of the anti-epileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem. Res. 18, 485-502.
29. Maguire, C., Regan, C.M., 1991. In vitro screening for anticonvulsant-induced teratogenesis: drug alteration of cell adhesivity. Int. J. Dev. Neurosci. 9, 581-586.
30. Martin, M.L., Regan, C., 1988. The anticonvulsant sodium valproate specifically induces the expression of a rat glial heat shock protein which is identified as the collagen type IV receptor. Brain Res. 459, 131-137.
31. Martin, M.L., Regan, C.M., 1991. The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase. Brain Res. 554, 223-228.
32. Martin, M.L., Breen, K.C., Regan, C.M., 1988. Perturbations of cellular functions integral to neural tube formation by the putative teratogen sodium valproate. Toxicol. Vitro 2, 43-48.
33. Nau, H., 1986a. Valproic acid teratogenicity in mice after various administration and phenobarbital-pretreatment regimens: The parent drug and not one of the metabolites assayed is implicated as teratogen. Fundam. Appl. Toxicol. 6, 662-668.
34. Nau, H., 1986b. Transfer of valproic acid and its main active unsaturated metabolite to gestational tissue: correlation with neural tube defect formation in the mouse. Teratology 33, 21-27.
35. Nau, H., Hendrickx, A.G., 1987. Valproic acid teratogenesis. ISI Atlas Sci. Pharmacol. 1, 152-156.
36. Nau, H., Löscher, W., 1986. Pharmacological evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundam. Appl. Toxicol. 6, 669-676.
37. Nau, H., Zierer, R., Spielmann, H., Neubert, D., Gansau, C., 1981a. A model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. Life Sci. 29, 2803-2814.
38. Nau, H., Rating, D., Koch, S., Häuser, I., Helge, H., 1981b. Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. J. Pharmacol. Exp. Ther. 219, 768-777.
39. Nau, H., Hauck, R.-S., Ehlers, K., 1991. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol. 69, 310-321.
40. O'Brien, E., Regan, C.M., 1998. Protein kinase C inhibitors arrest the C6 glioma cell cycle at a mid-G1 phase restriction point: implications for the antiproliferative action of valproate. Toxicol. Vitro 12, 9-14.
41. Perlman, B.J., Goldstein, D.B., 1984. Membrane disordering potency and anticonvulsant action of valproic acid and other short chain fatty acids. Mol. Pharmacol. 26, 83-89.
42. Plioplys, A.V., Hemmens, S.E., Regan, C.M., 1990. Expression of a NCAM serum fragment is depressed in autism. J. Neuropsychiatry Clin. Neurosci. 2, 413-417.
43. Regan, C.M., 1985. Therapeutic levels of sodium valproate inhibit mitotic indices in cells of neural origin. Brain Res. 347, 394-398.
44. Regan, C.M., Larsson, O.M., Martin, M.L., Schousboe, A., Williams, D.C., 1991. In vitro screening for anticonvulsant-induced teratogenesis: Structure - activity relationships in the barbiturate and branched chain carboxylic acid classes. Toxicol. Vitro 5, 77-82.
45. Rheinhold, D.S., Neet, K.E., 1989. The lack of a role for protein kinase C in neurite extension and in the induction of ornithine decarboxylase by nerve growth factor in PC 12 cells. J. Biol. Chem. 264, 3538-3544.
46. Sandig, M., Rao, Y., Kalnins, V.I., Siu, C.-H., 1996. Integrity of the homophilic binding site is required for the preferential localization of NCAM in intercellular contacts. Biochem. Cell Biol. 74, 373-381.
47. Sanford, K.K., Earle, W.R., Evans, V.J., Waltz, H.K., Shannon, J.E., 1951. The measurement of proliferation in tissue culture by enumeration of cell nuclei. J. Natl. Cancer Inst. 11, 773-795.
48. Scott, W.J. Jr., Collins, M.D., Nau, H., 1994. Pharmacokinetic determinants of embryotoxicity in rats associated with organic acids. Environ. Health Perspect. 102 (Suppl. II), 97-102.
49. Slater, S.J., Cox, K.J.A., Lombardi, J.V., Ho, C., Kelly, M.B., Rubin, E., Stubbs, C.D., 1993. Inhibition of protein kinase C by alcohols and anesthetics. Nature 364, 82-84.
50. Sporns, O., Edelman, G.M., Crossin, K.L., 1995. The neural cell adhesion molecule (N-CAM) inhibits proliferation in primary cultures of rat astrocytes. Proc. Natl. Acad. Sci. USA 92, 542-546.
51. Sturrock, J., Nunn, J.F., 1976. Effects of halothane on DNA synthesis and the presynthetic phase (G1) in dividing fibroblasts. Anaesthesiology 45, 413-420.
52. Turner, S., Sucheston, M.E., de Philip, R.M., Paulson, R.B., 1990. Teratogenic effects on the neuroepithelium of the CD-1 mouse embryo exposed in utero to sodium valproate. Teratology 41, 421-442.
53. Walsh, F.S., Doherty, P., 1997. Neural cell adhesion molecules of the immunoglobulin superfamile: role in axon growth and guidance. Annu. Rev. Cell Dev. Biol. 13, 425-456.
54. Wilder, B.J., Karas, B.J., 1982. Valproate: relation of plasma concentration to seizure control. In: Woodbury, D.M., Penry, J.K., Pippenger, C.E. (Eds.), Antiepileptic Drugs, 2nd edn. Raven Press, New York, pp. 591-599.